Research at Oslo University Hospital

Molecular biologist Anita Sveen and surgeon Pål-Dag Line join forces in a new project to improve the patient benefit from liver transplantation of metastatic colorectal cancer. This is a collaborative effort between Dept Molecular Oncology (KRE) and Dept Transplantation Medicine (KIT)

The project is a translational substudy of ongoing clinical studies and will generate the first large-scale molecular and pharmacological data of transplantable metastatic colorectal cancers. This project was recently supported by a research grant from the Norwegian Cancer Society.

Maja Radulovic, postdoc in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Cell Reprogramming, has previously shown that a molecular machinery known as ESCRT contributes to repair damaged lysosomes. Now, Maja and her co-workers have revealed an additional mechanism that contributes to lysosome repair, namely lipid transfer from the endoplasmic reticulum (ER). The results are published in the prestigious EMBO Journal, in an article entitled "Cholesterol transfer via endoplasmic reticulum contacts mediates lysosome damage repair".

Marina Vietri from the Department of Molecular Cell Biology is this year's winner of the prestigious Dr. Ragnar Mørk's Prize for cancer research.

She has won the award of NOK 200.000 for her pioneering studies of nuclear envelope sealing in genome integrity and cancer progression.

The prize ceremony took place on 25th of November in the Auditorium of Institute for Cancer Research.

Earlier this year Marina Vietri was awarded the NFR Young Research Talent grant.

A study led by Anne Hege Aamodt, head of the "Stroke, headache and covid research group" at the Department of Neurology and cardiologist Dan Atar has shown that atrial fibrillation is the hidden cause of stroke in many patients, and that long-term heart rhythm monitoring of patients can prevent recurrent strokes in this group.
The results are presented in the European Stroke Journal. The findings have been summarized in a news article on sciencenorway.no, the English version of the award-winning popular science web site forskning.no, and presented via major Norwegian news outlets.

Anita Sveen, project group leader and member of the Lothe lab at the Department of Molecular Oncology at the Institute for Cancer research, was invited speaker at the AACR special conference colorectal cancer, held October 1-4th in Portland, Oregon, USA.
In her well received speech Dr. Sveen presented the multidisciplinary work from the TEAM-ACT (Tumor Evolution in Advanced Models to Accelerate precision Cancer Therapy) - a strategic research area of OUS. 

Integreat - The Norwegian centre for knowledge-driven machine learning - has been selected as a new Center of Exellence. Arnoldo Frigessi will head Integreat for the first three years. He is the director of the Oslo Centre for Biostatistics & Epidemiology (OCBE), a joint center integrating the activities of biostatistics departments at the University of Oslo and Oslo University Hospital.

The nine new centers appointed by the Norwegian Research Council will each receive NOK 155 million.

In June last year, 36 applicants were invited to further develop their applications. The funding for the nine centers were granted at a meeting on 22 September.  

On September 23rd he Research Council of Norway published the results of the latest Centre of Excellence call.
The PRecision Immunotherapy Alliance (PRIMA) was funded as a CoE with 155 mNOK over 10 years.

The center will have Kalle Malmberg and Johanna Olweus as co-directors and includes their groups and that of June Myklebust (PI) at ICR, and also Ludvig Munthe, Jan Terje Andersen and Fridtjof Lund-Johansen at Department of Immunology and Transfusion Medicine (RH) as well as Emma Haapaniemi (NCMM) as PIs and with UiO as host and OUH as partner.

The Tumour Marker Group at the Department of Medical Biochemistry, OUH-Radiumhospitalet, is part of the European SQUEEZE consortium, which in total receives more than NOK 100 million from the EU through the Horizon Europe 2022 call. 

"We are proud to provide analyses of serum drug and anti-drug antibody concentrations in such a prestigious and ambitious European collaboration", says senior consultant and research group leader Nils Bolstad.